CDNA
CareDx, Inc.
stockNASDAQ
caredx: transforming transplant patient care through novel surveillance management solutions caredx, inc. is dedicated to improving the lives of organ transplant patients through non-invasive diagnostics. by combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, caredx is at the forefront of organ transplant surveillance and pre-transplant hla typing solutions. nasdaq:cdna about allosure® allosure is the first and only non-invasive blood test that directly measures allograft injury and identifies the probability of active rejection to better manage kidney transplant patients. allosure is a clinical-grade, proprietary next-generation sequencing (ngs) based test to detect donor-derived cell-free dna (dd-cfdna) in order to identify organ injury in kidney transplant recipients. allosure is analytically validated as a sensitive, specific, and precise measurement of dd-cfdna. allos
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 64.60 | 2026-09-28 | +4.03% | 1.194 |
| 1M | 50.88 | 2026-09-04 | +32.08% | 0.679 |
| 3M | 29.06 | 2026-07-06 | +131.25% | 1.294 |
| 6M | 17.82 | 2026-04-06 | +277.10% | 0.920 |
| 1Y | 15.19 | 2025-10-03 | +342.40% | 1.340 |
| 2Y | 30.91 | 2024-10-04 | +117.41% | — |
| 5Y | 63.37 | 2021-10-04 | +6.04% | 1.549 |
CareDx, Inc. (NASDAQ:CDNA) stock price today is $67.20, and today's volume is 1,588,487. CDNA is up 1.465% today. The 30 day average volume is 1.30M. CDNA market cap is $3.48B with 51.73M shares outstanding.